Most cases of gastroparesis are considered idiopathic, meaning they have no clear cause
Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): A substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
Any decision should follow the guidance of the surgical, anesthesia, and prescribing teams, tailored to your procedure and individual risk
In the UK, while the Wegovy licence covers adults with BMI 30 kg/m or 27 kg/m with weight-related comorbidities, NHS availability through NICE TA875 is more restrictedtypically to specialist weight management services for those with BMI 35 kg/m (or 30 kg/m with weight-related comorbidities) and limited to a maximum of 2 years
Each batch is provided with lot-specific analytical documentation for identity and purity
Ozempic is approved for type 2 diabetes management and is widely prescribed off-label for weight loss